TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB10392

Activity

Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia Antifungipept CAFPdb HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0

Sequence_Type

standard

Has_Modification No

Description A 24-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Sequence

FLPLIAGVAASILPKIFCFITKKC

FASTA

>TPDB10392|Antibacterial;Anticancer;Antifungal;Antiparasitic;Hemolysis;Toxicity|length=24
FLPLIAGVAASILPKIFCFITKKC

Formula C126H205N27O27S2

Absent Amino Acids RNDEQHMWY

Common Amino Acids I

Mass 2594.30

PI 9.80

Basic Residues 3

Acidic Residues 0

Hydrophobic Residues 14

Net Charge +3

Boman Index -3.08

Hydrophobicity 1.483

Aliphatic Index 138.33

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 125

Absorbance 280nm 4.82

Polar Residues 4

number

3

A

0

R

0

N

0

D

2

C

0

E

0

Q

1

G

0

H

4

I

3

L

3

K

0

M

3

F

2

P

1

S

1

T

0

W

0

Y

1

V

Amino Acid Distribution

A: 3 R: 0 N: 0 D: 0 C: 2 E: 0 Q: 0 G: 1 H: 0 I: 4 L: 3 K: 3 M: 0 F: 3 P: 2 S: 1 T: 1 W: 0 Y: 0 V: 1

Length

24

Formula

C126H205N27O27S2

Mass

2594.30

PI

9.80

Net Charge

+3

Boman Index

-3.08

Hydrophobicity

1.483

Evidence 1 Activity

Activity

Activity Endpoint LC50

Detail Source Activity Hemolysis

Activity Measurement 5 mM

Hemolysis Raw

[Ref.19379837] LC50=5 mM against human erythrocytes

Target

RBC Target human erythrocytes

Source & Reference

Database Source Hemolytik PD_Hemolysis

Source DRAMP4

Reference

Comp Biochem Physiol C Toxicol Pharmacol. 2009 Aug 150(2):150-154.

Other

Source Activity Label	Source Definition
Hemolysis	Hemolytik experimentally validated hemolytic peptide annotation.

Evidence 2 Activity

Activity

Activity Endpoint 50% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 5 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

50% Hemolysis | 5 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Purification of peptides with differential cytolytic activities from the skin secretions of the Central American frog, Lithobates vaillanti (Ranidae). | Comp Biochem Physiol C Toxicol Pharmacol | 2009

Evidence 3 Activity

Activity

Activity Endpoint LC50

Detail Source Activity Toxicity

Activity Measurement 5 mM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

Hemolytic_activity: [Ref.19379837] LC50=5 mM against human erythrocytes | Cytotoxicity: [Ref.19379837] LC50=7mM against HepG2 hepatoma-derived cells

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

Comp Biochem Physiol C Toxicol Pharmacol. 2009 Aug 150(2):150-154.

Evidence 4 Hemolysis

Activity

Activity Measurement 5 mM

Activity Endpoint LC50

Hemolysis Raw

[Ref.19379837] LC50=5 mM against human erythrocytes

Detail Source Activity Hemolysis

Target

RBC Target human erythrocytes

Source & Reference

source HemoPI PD_Hemolysis

Reference

Comp Biochem Physiol C Toxicol Pharmacol. 2009 Aug 150(2):150-154.

Source DRAMP4

Database Source PD_Hemolysis